EPHA10 as a Radioligand Therapy Target
EPHA10, EPH receptor A10, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, EPHA10 staining is highest in skin cancer (92% of samples positive), head and neck cancer (75% of samples positive) and cervical cancer (50% of samples positive). Published literature reports that EPHA10 internalizes after ligand binding, which helps retain a radionuclide inside tumor cells. Clinical status: Discovery-stage (no clinical drug program).
Is EPHA10 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in skin cancer, 92% of samples positive.
- ✅ Internalization: Reported to internalize, which favors radionuclide retention.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
EPHA10 expression in cancer
Protein expression of EPHA10 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Skin Cancer | 0.69 | High | 92% |
| Head and Neck Cancer | 0.25 | Medium | 75% |
| Cervical Cancer | 0.25 | Medium | 50% |
| Thyroid Cancer | 0.17 | Low | 50% |
| Pancreatic Cancer | 0.17 | Low | 42% |
| Glioma | 0.10 | Low | 30% |
| Lung Cancer | 0.10 | Low | 20% |
| Melanoma | 0.09 | Low | 18% |
| Neuroendocrine Tumors | 0.08 | Low | 25% |
| Lymphoma | 0.06 | Low | 8% |
| Gastric Cancer | 0.04 | Low | 11% |
| Colorectal Cancer | 0.03 | Low | 8% |
| Ovarian Cancer | 0.03 | Low | 8% |
| Bladder Cancer | 0.03 | Low | 8% |
| Liver Cancer | 0.03 | Low | 8% |
Not detected by IHC in: breast cancer, kidney cancer, prostate cancer, testicular cancer, endometrial cancer.
Is EPHA10 internalized?
Yes. The results of the intracellular colocalization study indicated that DOX + siRNA/ePL possessed the ability for pH-responsive rapid endosomal escape... specifically accumulate in the tumor cells via receptor-mediated endocytosis after intravenous administration into the blood system.
Sources: PMID 29798663. AI-extracted from abstracts, so verify before citing.
EPHA10 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for EPHA10 yet. Search ClinicalTrials.gov for EPHA10 trials.
EPHA10 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See EPHA10 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
EPHA10 gene essentiality (DepMap)
CRISPR knockout effect across 1253 cancer cell lines: -0.10 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related skin cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · B7-H3 (CD276) · SSTR2 · ITGB6 · HER2 (ERBB2) · ITGAV
See all radioligand therapy targets in skin cancer.
See how EPHA10 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.